WEST PHARMACEUTICAL SERVICES INC WST
Surgical & Medical Instruments & Apparatus ยท NYSE
์์ต
$2.95B
+2.2% ๋
๋๋
๋
์์์ต
$593.40M
+1.3% ๋
๋๋
๋
์ด ์์ฐ
$3.64B
-4.9% ๋
๋๋
๋
EPS
7.88
+1.9% ๋
๋๋
๋
Advertisement
Income Statement
| ๊ธฐ๊ฐ | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $2.27B | $1.46B | $698.00M | $2.95B | $2.14B | $1.40B | $695.40M | $2.89B |
| Gross Profit | $800.10M | $505.80M | $231.90M | $1.13B | $724.90M | $460.20M | $230.20M | $1.14B |
| R&D Expense | $52.50M | $35.40M | $16.30M | $68.40M | $50.60M | $35.10M | $17.60M | $58.50M |
| SG&A Expense | $286.60M | $183.90M | $88.00M | $353.40M | $253.20M | $169.70M | $86.70M | $316.90M |
| Operating Income (Loss) | $428.30M | $260.70M | $107.00M | $676.00M | $410.30M | $249.00M | $122.80M | $734.00M |
| Interest Expense | โ | โ | โ | โ | โ | โ | โ | โ |
| Net Income (Loss) | $89.80M | $89.80M | $89.80M | $593.40M | $115.30M | $115.30M | $115.30M | $585.90M |
| EPS (Diluted) | 4.97 | 3.05 | 1.23 | 7.88 | 4.91 | 3.06 | 1.55 | 7.73 |
์ฌ๋ฌดํ
| ๊ธฐ๊ฐ | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.27B | $4.27B | $4.27B | $3.64B | $3.64B | $3.64B | $3.64B | $3.83B |
| Current Assets | $1.98B | $1.98B | $1.98B | $1.54B | $1.54B | $1.54B | $1.54B | $1.94B |
| Cash & Equivalents | $791.30M | $791.30M | $791.30M | $484.60M | $484.60M | $484.60M | $484.60M | $853.90M |
| Accounts Receivable | $574.40M | $574.40M | $574.40M | $552.50M | $552.50M | $552.50M | $552.50M | $512.00M |
| Inventory | $443.90M | $443.90M | $443.90M | $377.00M | $377.00M | $377.00M | $377.00M | $434.70M |
| PP&E (Net) | $1.73B | $1.73B | $1.73B | $1.58B | $1.58B | $1.58B | $1.58B | $1.41B |
| Goodwill | $109.90M | $109.90M | $109.90M | $108.50M | $106.00M | $106.00M | $106.00M | $107.30M |
| Total Liabilities | $1.09B | $1.09B | $1.09B | $961.10M | $961.10M | $961.10M | $961.10M | $948.50M |
| Current Liabilities | $654.90M | $654.90M | $654.90M | $550.40M | $550.40M | $550.40M | $550.40M | $671.80M |
| Accounts Payable | $253.70M | $253.70M | $253.70M | $239.30M | $239.30M | $239.30M | $239.30M | $242.40M |
| Long-Term Debt | $202.80M | $202.80M | $202.80M | $202.60M | $202.60M | $202.60M | $202.60M | $206.80M |
| Stockholders Equity | $2.68B | $2.68B | $2.68B | $2.68B | $2.88B | $2.88B | $2.88B | $2.34B |
Cash Flow Statement
| ๊ธฐ๊ฐ | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $503.70M | $306.50M | $129.40M | $776.50M | $463.30M | $283.20M | $118.20M | $724.00M |
| Investing Cash Flow | $-209.80M | $-146.50M | $-71.30M | $-368.70M | $-273.90M | $-191.80M | $-90.60M | $-288.20M |
| Financing Cash Flow | $-173.40M | $-161.90M | $-147.00M | $-459.60M | $-553.70M | $-489.30M | $-271.00M | $-293.60M |
| Stock Repurchases | $134.00M | $134.00M | $133.50M | $438.30M | $506.50M | $454.10M | $267.00M | $202.80M |
์ ์ฌ ๊ธฐ์
BAXTER INTERNATIONAL INC
BAX
BECTON DICKINSON & CO
BDX
BOSTON SCIENTIFIC CORP
BSX
DEXCOM INC
DXCM
3M CO
MMM
INSULET CORP
PODD
RESMED INC
RMD
Solventum Corp
SOLV
๋ ์์๋ณด๊ธฐ
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
๋ฐ์ดํฐ๋ ๋ฏธ๊ตญ SEC EDGAR ๊ณต๊ณต ๋ฐ์ดํฐ๋ฒ ์ด์ค์์ ์์ง๋์์ต๋๋ค. ์ด ์ฌ์ดํธ๋ ํฌ์ ์กฐ์ธ์ ์ ๊ณตํ์ง ์์ต๋๋ค.